“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.
In this video, Jennifer A. Linehan, MD, discusses her clinical practice and experience with high-intensity focused ultrasound (HIFU) for patients with prostate cancer. Linehan is an associate professor of urology and urologic oncology at Saint John’s Cancer Institute in Santa Monica, California.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.